52 Participants Needed

Treprostinil for Pulmonary Arterial Hypertension

(ARTISAN Trial)

Recruiting at 30 trial locations
ML
Overseen ByMary Lou Tomson
Age: 18+
Sex: Any
Trial Phase: Phase 4
Sponsor: United Therapeutics
Must be taking: Endothelin antagonists, PDE-5 inhibitors
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

The primary objective of this study is to assess the effect of early and rapid treprostinil therapy for mean pulmonary artery pressure (mPAP) reduction to improve right ventricular (RV) function and reverse RV remodeling in participants with pulmonary arterial hypertension (PAH).

Will I have to stop taking my current medications?

The trial does not specify if you need to stop your current medications, but you must be on a stable dose of certain medications like endothelin receptor antagonists or phosphodiesterase type 5 inhibitors, or be willing to start them along with the study drug.

How is the drug Treprostinil unique for treating pulmonary arterial hypertension?

Treprostinil is unique because it is available in multiple forms, including oral, inhaled, and injectable, which offers flexibility in administration. The oral form, Orenitram, is particularly novel as it provides the convenience of oral dosing, potentially improving patient compliance compared to other prostacyclin analogues that require more complex administration.12345

What data supports the effectiveness of the drug Treprostinil for treating pulmonary arterial hypertension?

Treprostinil, available in oral, inhaled, and injectable forms, has shown improvements in exercise capacity and survival in patients with pulmonary arterial hypertension. The oral form, Orenitram, offers the convenience of oral dosing and has been approved by the FDA after demonstrating improved exercise capacity in clinical trials.12456

Are You a Good Fit for This Trial?

This trial is for people with pulmonary arterial hypertension (PAH) who have a mean pulmonary artery pressure over 35 mmHg and are on stable PAH medication or willing to start it. They should be able to walk more than 165 meters, not have severe liver issues, and can't be using certain other medications or have conditions that affect heart imaging tests.

Inclusion Criteria

Before joining the study, your heart catheterization must meet certain measurements, and you must be on specific medications for your condition.
My PAH is related to genetics, drugs (not amphetamines), heart repair, connective tissue disease, or HIV.

Exclusion Criteria

Criterion Summary: You will be excluded from the study if you have used specific medications, have certain types of pulmonary hypertension, have used certain drugs within the past year, have certain medical conditions, have used other investigational treatments recently, or have certain cardiac conditions or implants that could interfere with the study.
I have not had a CardioMEMS sensor implanted and can take blood thinners for 30 days post-implant.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive early and rapid treprostinil therapy to reduce mean pulmonary artery pressure and improve right ventricular function

36 months
Monthly visits for mPAP assessments and dose adjustments

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Oral Treprostinil
  • Parenteral Treprostinil
Trial Overview The study is testing the effectiveness of Treprostinil therapy administered early and rapidly in two forms—parenteral (injected) and oral—to lower high blood pressure in the lungs' arteries, improve heart function on the right side, and reverse changes due to PAH.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: TreprostinilExperimental Treatment2 Interventions
Participants will receive parenteral treprostinil at initial dose of 1.25 nanograms/kilogram/minute (at minimum) either intravenously or subcutaneously. Based on mPAP assessments and after a minimum dose of parenteral treprostinil is reached, at Investigator's (PI's) discretion, participants may transition to oral treprostinil and continue dose uptitration for further reduction of mPAP. Based on Month 12 mPAP assessment, participants may transition from parenteral to oral treprostinil at PI's discretion after completion of Month 12 assessment and continue uptitration for further reduction of mPAP. If minimum dose of parenteral treprostinil is not reached at Month 6/12 at PI's discretion, uptitration of parenteral treprostinil or oral treprostinil transition may occur to maintain normal mPAP. Treprostinil therapy (parenteral or oral) may continue as tolerated toward goal of further reduction of mPAP until Month 36.

Oral Treprostinil is already approved in United States, Canada, European Union for the following indications:

🇺🇸
Approved in United States as Remodulin for:
  • Pulmonary arterial hypertension (PAH)
  • Pulmonary hypertension associated with interstitial lung disease
🇨🇦
Approved in Canada as Remodulin for:
  • Long-term treatment of pulmonary arterial hypertension in NYHA Class III and IV patients who did not respond adequately to conventional therapy
🇪🇺
Approved in European Union as Treprostinil for:
  • Pulmonary arterial hypertension (PAH)

Find a Clinic Near You

Who Is Running the Clinical Trial?

United Therapeutics

Lead Sponsor

Trials
112
Recruited
14,500+

Dr. Martine Rothblatt

United Therapeutics

Chief Executive Officer since 1996

PhD in Medical Ethics from the Royal London College of Medicine and Dentistry, JD and MBA from UCLA

Dr. Michael Benkowitz

United Therapeutics

Chief Medical Officer since 2023

MD from Harvard Medical School

Lung Biotechnology PBC

Industry Sponsor

Trials
14
Recruited
710+

Published Research Related to This Trial

Treprostinil is an effective treatment for pulmonary arterial hypertension (PAH) and is available in three formulations: intravenous/subcutaneous (Remodulin®), inhaled (Tyvaso®), and oral (Orenitram®).
Pharmacokinetic studies in both healthy volunteers and PAH patients provide important insights that can help clinicians make informed decisions about the most suitable route of administration for individual patients.
A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration.Kumar, P., Thudium, E., Laliberte, K., et al.[2018]
Treprostinil diolamine (Orenitram™) is a new oral formulation for treating pulmonary arterial hypertension (PAH) that offers similar pharmacokinetic properties to existing parenteral and inhaled therapies, potentially improving patient compliance due to its convenient oral dosing.
The FDA approved treprostinil diolamine after it demonstrated improved exercise capacity in patients with de novo PAH, indicating its efficacy as a monotherapy in this serious condition.
Oral treprostinil for the treatment of pulmonary arterial hypertension.de Lartigue, J.[2017]
In a study involving 30 subjects, including those with varying degrees of hepatic impairment, the pharmacokinetics of oral treprostinil showed that its clearance decreased significantly with worsening liver function, leading to increased drug exposure levels.
The most common side effects, such as headache, diarrhea, and nausea, were consistent with those seen in other studies of treprostinil, and their incidence increased with the severity of hepatic impairment, indicating the need for dosage adjustments in these patients.
An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment.Peterson, L., Marbury, T., Marier, J., et al.[2017]

Citations

A Comprehensive Review of Treprostinil Pharmacokinetics via Four Routes of Administration. [2018]
Oral treprostinil for the treatment of pulmonary arterial hypertension. [2017]
An evaluation of the pharmacokinetics of treprostinil diolamine in subjects with hepatic impairment. [2017]
Pharmacokinetics of 3 times a day dosing of oral treprostinil in healthy volunteers. [2017]
Comparative bioavailability of inhaled treprostinil administered as LIQ861 and Tyvaso® in healthy subjects. [2021]
Parenteral treprostinil induction for rapid attainment of therapeutic doses of oral treprostinil. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security